IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.920
NA - Nord America 1.183
AS - Asia 535
OC - Oceania 7
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 3.651
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.177
SE - Svezia 1.006
IT - Italia 328
SG - Singapore 323
RU - Federazione Russa 311
CN - Cina 134
FI - Finlandia 74
IE - Irlanda 63
DE - Germania 46
IN - India 29
NL - Olanda 26
AE - Emirati Arabi Uniti 20
FR - Francia 13
CH - Svizzera 9
GB - Regno Unito 9
AU - Australia 6
BE - Belgio 6
CA - Canada 6
IR - Iran 6
CZ - Repubblica Ceca 4
ES - Italia 4
MV - Maldive 4
PH - Filippine 4
PL - Polonia 4
TW - Taiwan 4
UA - Ucraina 4
HK - Hong Kong 3
NO - Norvegia 3
AR - Argentina 2
DK - Danimarca 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
HU - Ungheria 2
IQ - Iraq 2
KZ - Kazakistan 2
MK - Macedonia 2
FJ - Figi 1
IL - Israele 1
JP - Giappone 1
MY - Malesia 1
OM - Oman 1
RO - Romania 1
SI - Slovenia 1
Totale 3.651
Salva come PNG Salva come JPEG
Città #
Lawrence 328
Princeton 328
Ashburn 187
Singapore 181
Milan 168
Moscow 135
Shanghai 113
Helsinki 71
New York 69
Dublin 63
Boardman 41
Rome 28
Dubai 20
Seattle 18
Pune 16
Ridgewood 14
Los Angeles 12
Dronten 10
Zurich 9
Washington 8
Meppel 6
Mol 6
Nuneaton 6
Borås 5
Cesano Boscone 5
Taranto 5
Turin 5
Ferrara 4
Male 4
Mountain View 4
Prague 4
Redwood City 4
Warsaw 4
Bari 3
Chennai 3
Dasmariñas 3
Genoa 3
Hangzhou 3
Lappeenranta 3
Reggio Emilia 3
Signa 3
Sydney 3
Verona 3
Andria 2
Astana 2
Athens 2
Baghdad 2
Banqiao 2
Barcelona 2
Bergen 2
Berlin 2
Budapest 2
Caerano di San Marco 2
Cairo 2
Catania 2
Creon 2
Duncan 2
Frankfurt am Main 2
Freiburg im Breisgau 2
Gorle 2
Guangzhou 2
Hanover 2
Hong Kong 2
Hyderabad 2
Las Vegas 2
Madrid 2
Melbourne 2
Modena 2
Mumbai 2
Nagpur 2
Padova 2
Paris 2
Perugia 2
Piacenza 2
Pistoia 2
Reggio Calabria 2
Romainville 2
Sacramento 2
Santena 2
Skopje 2
Soveria Mannelli 2
Strasbourg 2
Taipei 2
Tampa 2
Toronto 2
Torre Del Greco 2
Treviolo 2
Vellore 2
Zanjan 2
Zhengzhou 2
Alessandria 1
Amsterdam 1
Andover 1
Anzio 1
Astoria 1
Baguio City 1
Bergamo 1
Bordeaux 1
Boydton 1
Buenos Aires 1
Totale 2.015
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 43
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 32
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 26
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 24
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 21
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 21
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 21
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 21
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 20
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 19
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 19
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 18
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 18
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 18
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 18
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 18
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 18
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 18
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 18
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL) 18
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases 17
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 17
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 17
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 17
A woman and her canary: a tale of chlamydiae and lymphomas 17
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 17
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 17
HIGHER ORDER IMMUNOGLOBULIN REPERTOIRE RESTRICTIONS IN CLL: THE ILLUSTRATIVE CASE OF STEREOTYPED SUBSETS #2 AND #169 17
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 17
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) 17
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 17
Chronic lymphocytic leukemia 16
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 16
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 16
Monoclonal B-cell lymphocytosis: right track or red herring? 16
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 16
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 16
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 16
Clonal B-cell lymphocytosis: a new member? 16
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 16
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 16
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results 16
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 16
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 16
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 16
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 15
Monoclonal CD5(+) and CD5(-) B-lymphocyte expansions are frequent in the peripheral blood of the elderly 15
In vitro growth of human multiple myeloma: implications for biology and therapy 15
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 15
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 15
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor 15
Targeting B-cell anergy in chronic lymphocytic leukemia. 15
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 15
V delta 1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 15
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation 15
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 15
A new life for rituximab? 15
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 15
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 14
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 14
Is good clinical practice becoming poor clinical care? 14
A frequent EcoRI polymorphism in the bcl-2 gene 14
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 14
KAP1 regulates gene networks controlling mouse B-lymphoid cell differentiation and function 14
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 14
The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia 14
The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL 14
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials 14
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project 14
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 14
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion 14
Relevance of Minimal Residual Disease in the Era of Targeted Agents 14
Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset 8 14
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 13
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 13
Another piece of the puzzle: is there a "nodal" monoclonal B-cell lymphocytosis? 13
MBL Versus CLL How Important Is the Distinction? 13
Antigen selection in B-cell lymphomas-Tracing the evidence 13
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 13
Cytokines involved in the progression of multiple myeloma 13
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 13
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 13
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 13
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL 13
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 13
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 13
Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci 13
Chronic lymphocytic leukaemia 13
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia 13
B cell anergy modulated by TLR1/2 and the MIR-17∼92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4 13
Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia 13
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 13
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL) 13
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 13
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 13
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 13
The evolving treatment landscape of chronic lymphocytic leukemia 13
High-throughput analysis of the T-cell receptor gene repertoire in low-count monoclonal B-cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia 13
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 13
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 13
Totale 1.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.837
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011 11 0 0 0 0 0 0 0 0 0 0 0
2020/202151 0 0 0 0 22 25 3 0 1 0 0 0
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/2025636 636 0 0 0 0 0 0 0 0 0 0 0
Totale 3.978